Stratos Wealth Partners LTD. boosted its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) by 13.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,935 shares of the company's stock after acquiring an additional 2,865 shares during the period. Stratos Wealth Partners LTD. owned 0.15% of Global X Genomics & Biotechnology ETF worth $313,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Avidian Wealth Solutions LLC boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 6.8% during the 2nd quarter. Avidian Wealth Solutions LLC now owns 12,302 shares of the company's stock worth $150,000 after buying an additional 788 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Global X Genomics & Biotechnology ETF by 3.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 46,389 shares of the company's stock worth $567,000 after purchasing an additional 1,515 shares during the period. Insight Advisors LLC PA raised its position in shares of Global X Genomics & Biotechnology ETF by 5.5% during the second quarter. Insight Advisors LLC PA now owns 31,675 shares of the company's stock worth $486,000 after purchasing an additional 1,655 shares during the period. McGuire Investment Group LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 0.4% during the second quarter. McGuire Investment Group LLC now owns 525,886 shares of the company's stock worth $6,426,000 after purchasing an additional 1,900 shares during the period. Finally, HighTower Advisors LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 3.6% during the first quarter. HighTower Advisors LLC now owns 62,395 shares of the company's stock worth $939,000 after purchasing an additional 2,140 shares during the period.

Global X Genomics & Biotechnology ETF Stock Down 0.2 %

Shares of NASDAQ:GNOM opened at $12.79 on Friday. Global X Genomics & Biotechnology ETF has a twelve month low of $10.48 and a twelve month high of $18.59. The stock's 50 day moving average is $12.97 and its 200-day moving average is $13.41.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

Featured Articles

• Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
• MarketBeat: Week in Review 01/02-01/06
• Why is the CrowdStrike Stock Price Struggling?
• Four Undervalued Healthcare Stocks for 2023
• WWE Stock: Vince McMahon Wants Back In The Show
• NVIDIA Is Bottoming But Don't Buy It Just Yet

Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.